Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.56 |
| ▸ | DDB1 | Q16531 | 7/20 | 0.56 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21933426 | 1.00 | CRBN (0.56) | CRBNDDB1USP30 | |
| SCHEMBL31134689 | 0.96 | CRBN (0.53) | CRBNDDB1USP30 | |
| SCHEMBL25631526 | 0.94 | CRBN (0.51) | CRBNDDB1USP30 | |
| SCHEMBL29265369 | 0.91 | CRBN (0.50) | CRBNDDB1USP30 | |
| SCHEMBL30906296 | 0.91 | CRBN (0.50) | CRBNDDB1USP30 | |
| SCHEMBL30906259 | 0.91 | CRBN (0.50) | CRBNDDB1USP30 | |
| SCHEMBL21876657 | 0.90 | CRBN (0.54) | CRBNDDB1USP30 | |
| SCHEMBL21935469 | 0.89 | CRBN (0.59) | CRBNDDB1 | |
| SCHEMBL31306725 | 0.88 | CRBN (0.52) | CRBNDDB1USP30 | |
| SCHEMBL20046703 | 0.88 | CRBN (0.57) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688149-A1 | IRAK4 PROTACS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| EP-4676922-A1 | BIFUNCTIONAL COMPOUNDS CAPABLE OF DEGRADING ANDROGEN RECEPTORS | Astrazeneca AB (SE) | 2026-01-14 | — | — | EP | disclosed |
| EP-4561999-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | Abbvie Operations Singapore Pte. Ltd. (SG) | 2025-06-04 | — | — | EP | disclosed |
| US-20240374588-A1 | IRAK4 PROTACS | ASTRAZENECA AB (SE) | 2024-11-14 | — | — | US | disclosed |
| WO-2024209044-A1 | IRAK4 PROTACS | ASTRAZENECA AB (SE) | 2024-10-10 | — | — | WO | disclosed |
| WO-2024189488-A1 | BIFUNCTIONAL COMPOUNDS CAPABLE OF DEGRADING ANDROGEN RECEPTORS | ASTRAZENECA AB (SE) | 2024-09-19 | — | — | WO | disclosed |
| WO-2024026081-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | RIBON THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374588-A1 | IRAK4 PROTACS | IRAK4, IRAK2, IRAK3 | CRBN 99/4885DDB1 728/4885USP30 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.